Prostate-specific antigen velocity and repeated measures of prostate- specific antigen

H Ballentine Carter, J. D. Pearson

Research output: Contribution to journalArticle

Abstract

Numerous studies evaluating different populations have shown similar findings with respect to repeated PSA measurements and PSAV. First, there is substantial within-individual variability between repeated PSA measures. Second, this variability between PSA measurements precludes the use of a simple change in PSA as a marker for prostate cancer. Third, when one adjusts the changes that occur in PSA over an elapsed time of 1.5 to 2 years (PSAV), less than 5% of men without prostate, cancer will have a PSAV of 0.75 ng/mL/y or greater, and approximately 70% of men with prostate cancer will have a PSAV of 0.75 ng/mL/y or greater. These data strongly suggest that PSAV is a specific marker for the presence of prostate cancer.

Original languageEnglish (US)
Pages (from-to)333-338
Number of pages6
JournalUrologic Clinics of North America
Volume24
Issue number2
DOIs
StatePublished - 1997

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Population

ASJC Scopus subject areas

  • Urology

Cite this

Prostate-specific antigen velocity and repeated measures of prostate- specific antigen. / Carter, H Ballentine; Pearson, J. D.

In: Urologic Clinics of North America, Vol. 24, No. 2, 1997, p. 333-338.

Research output: Contribution to journalArticle

@article{fa3d9034739d4689aa6cca6fea7272b9,
title = "Prostate-specific antigen velocity and repeated measures of prostate- specific antigen",
abstract = "Numerous studies evaluating different populations have shown similar findings with respect to repeated PSA measurements and PSAV. First, there is substantial within-individual variability between repeated PSA measures. Second, this variability between PSA measurements precludes the use of a simple change in PSA as a marker for prostate cancer. Third, when one adjusts the changes that occur in PSA over an elapsed time of 1.5 to 2 years (PSAV), less than 5{\%} of men without prostate, cancer will have a PSAV of 0.75 ng/mL/y or greater, and approximately 70{\%} of men with prostate cancer will have a PSAV of 0.75 ng/mL/y or greater. These data strongly suggest that PSAV is a specific marker for the presence of prostate cancer.",
author = "Carter, {H Ballentine} and Pearson, {J. D.}",
year = "1997",
doi = "10.1016/S0094-0143(05)70380-3",
language = "English (US)",
volume = "24",
pages = "333--338",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Prostate-specific antigen velocity and repeated measures of prostate- specific antigen

AU - Carter, H Ballentine

AU - Pearson, J. D.

PY - 1997

Y1 - 1997

N2 - Numerous studies evaluating different populations have shown similar findings with respect to repeated PSA measurements and PSAV. First, there is substantial within-individual variability between repeated PSA measures. Second, this variability between PSA measurements precludes the use of a simple change in PSA as a marker for prostate cancer. Third, when one adjusts the changes that occur in PSA over an elapsed time of 1.5 to 2 years (PSAV), less than 5% of men without prostate, cancer will have a PSAV of 0.75 ng/mL/y or greater, and approximately 70% of men with prostate cancer will have a PSAV of 0.75 ng/mL/y or greater. These data strongly suggest that PSAV is a specific marker for the presence of prostate cancer.

AB - Numerous studies evaluating different populations have shown similar findings with respect to repeated PSA measurements and PSAV. First, there is substantial within-individual variability between repeated PSA measures. Second, this variability between PSA measurements precludes the use of a simple change in PSA as a marker for prostate cancer. Third, when one adjusts the changes that occur in PSA over an elapsed time of 1.5 to 2 years (PSAV), less than 5% of men without prostate, cancer will have a PSAV of 0.75 ng/mL/y or greater, and approximately 70% of men with prostate cancer will have a PSAV of 0.75 ng/mL/y or greater. These data strongly suggest that PSAV is a specific marker for the presence of prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0030993375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030993375&partnerID=8YFLogxK

U2 - 10.1016/S0094-0143(05)70380-3

DO - 10.1016/S0094-0143(05)70380-3

M3 - Article

VL - 24

SP - 333

EP - 338

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 2

ER -